CD274 and neoplasm: The CheckMate-032 trial showed that PD-L1 expression by CPS demonstrated a stronger association with overall survival at higher cutoffs than PD-L1 expression on tumor cells (response rates of PD-L1 cutoff: <1 vs. ≥1 vs. ≥5 vs. ≥10: 0% vs. 28% vs. 41% vs. 55%) (11).While the KEYNOTE-062 trial which enrolled 763 patients with untreated, locally advanced/unresectable or metastatic GC with PD-L1 CPS ≥1, also analysed the efficiency of the subgroup of CPS≥10 (23).